DADana P. Ascherman

Dana P. Ascherman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dana P. Ascherman has a total of 247 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis–Associated Lung Disease

    by Tracy Tabib, Ogechukwu Ezenwa, Joshua Sciurba, Eleanor B. Valenzi, John Sembrat, Brittany Cody, Jishnu Das, Robert Lafyatis, Dana P. Ascherman

    Objective: Rheumatoid arthritis (RA) often involves extra‐articular complications, including interstitial lung disease (ILD) and/or pulmonary nodules. Transcriptomic profiling of lung tissue provides the opportunity to directly assess cell‐specific gene expression and corresponding pathway activation in different types of rheumatoid lung disease. Methods: We used probe‐based, Flex single‐cell RNA sequencing (scRNA‐seq) of fixed lung tissue specimens to compare gene expression profiles in macrophage and fibroblast populations contributing to tissue remodeling in RA‐associated ILD (RA‐ILD) versus RA lung nodules. Additional comparison of differentially expressed genes (DEGs) in lung tissue explants from patients with idiopathic pulmonary fibrosis (IPF) elucidated the degree of overlap with RA‐ILD. Results: Flex scRNA‐seq of lung specimens from controls without disease (n = 4) and patients with RA‐ILD (n = 9) or RA nodules (n = 3) yielded clustering profiles mirroring uniform manifold approximation and projection distributions from conventional poly(A) capture–based scRNA‐seq of RA‐ILD, IPF, and control lung tissue. Comparative transcriptional profiling of macrophage and fibroblast subpopulations in RA‐ILD and RA lung nodules revealed only partial overlap, with differential up‐regulation of immunoregulatory, angioregulatory, and matrix assembly pathways in RA‐ILD fibroblasts that contrasted with selective up‐regulation of pathways promoting innate and adaptive immunity in macrophage populations comprising RA lung nodules. Comparison of DEGs between RA‐ILD and IPF lung‐derived macrophage and fibroblast populations demonstrated significant enhancement of profibrotic gene expression in both disease states. Conclusion: Flex scRNA‐seq of pulmonary macrophage and fibroblast subpopulations reveals key differences in transcriptional profile, distinguishing RA‐ILD from RA lung nodules. Parallel comparison of cell type–specific gene expression profiles between RA‐ILD and IPF demonstrates significant overlap in profibrotic transcriptional programs.


  • Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subgroups: Insights From a Single-Center Cohort

    by Nantakarn Pongtarakulpanit, Sidra Tahir, Varshapriya Suresh, Vaidehi Kothari, Shiri Keret, Eugenia Gkiaouraki, Siamak Moghadam-Kia, Vladimir M. Liarski, Dana P. Ascherman, Chester V. Oddis, et al.

    Objective: We evaluated remission rates and predictors across idiopathic inflammatory myopathy (IIM) subgroups using data from a prospective registry. Methods: Adult patients with IIM with ≥ 1 year of disease duration, enrolled between 2000 and 2019, were analyzed. Subgroups included dermatomyositis (DM), antisynthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM). Remission was defined as the absence of disease activity by expert assessment. Drug-free remission (DFR) and International Myositis Assessment and Clinical Studies Group (IMACS) remission (≥ 6 months of DFR) were also evaluated. Cumulative incidence of remission and flare was estimated using the cumulative incidence function. Remission predictors were evaluated using cause-specific Cox proportional hazards models. The association between remission and mortality was assessed using Cox models, with remission treated as a time-dependent covariate. Results: The cohort (n = 393) was 67.2% female, with a mean age of 50.1 years. At 10 years, cumulative probabilities of remission, DFR, and IMACS remission were 40.3%, 23.3%, and 18.1%, respectively. Remission rates were highest in DM (47.4%) and lowest in ASyS (30.1%). Median time to first remission was 3.7 years. The 10-year cumulative incidence of flare following remission was 40.6%. Anti–Mi-2 antibody predicted a higher likelihood of remission (hazard ratio 2.08, P = 0.02). Remission and DFR were associated with improved survival. Conclusion: Remission rates differed across IIM subgroups, with the highest in DM and lowest in ASyS. Anti–Mi-2 antibody was associated with a higher likelihood of remission.

  • Open Access

    Multimodal Integration of Protein Interactomes With Genomic and Molecular Data Discovers Distinct Rheumatoid Arthritis Endotypes

    by Javad Rahimikollu, Priyamvada Guha Roy, Akash Kishore, Danica Morgan Lee, Lauren A. Vanderlinden, Kiran Nazarali, Fan Zhang, Dana P. Ascherman, Daniella M. Schwartz, Larry Moreland, et al.

    Objective: Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease characterized by clinical and molecular heterogeneity, notably in the presence of anti–cyclic citrullinated peptide (CCP) antibodies. Patients with CCP+ RA exhibit more severe disease progression and distinct treatment responses compared to patients with CCP− RA. Although previous studies have investigated cellular and molecular differences between these subtypes, their genetic differences are understudied. Methods: We leveraged the Rheumatoid Arthritis Comparative Effectiveness Research cohort, comprising 555 patients with CCP+/rheumatoid factor (RF)+ RA and 384 patients with CCP−/RF+ RA. Using a novel framework, we integrated a network‐based genome‐wide association study (GWAS) with multiomic data to uncover corresponding genetic and molecular differences. Results: We uncovered a significant heritability difference between these disease groups. Network‐based GWAS uncovered 14 putative gene modules, including many genes outside the HLA loci, that explained genetic differences between CCP+/RF+ and CCP−/RF+ RA. Heritability partitioning and multivariate expression analyses validated four modules, highlighting novel genetic loci underlying phenotypic differences. Module functional significance was established using multiple orthogonal cohorts, underscoring their biologic relevance. Conclusion: Our findings demonstrate the use of network‐based approaches in revealing differential genetic risk factors underlying CCP+/RF+ and CCP−/RF+ RA. Disease‐associated gene modules detected in synovial tissue were also observed in peripheral blood, indicating joint‐specific molecular programs are reflected systemically. This cross‐tissue concordance highlights the potential for blood‐based assays to capture pathogenic mechanisms active in the joints, enabling practical patient stratification. Our findings highlight why patients with CCP+/RF+ and CCP−/RF+ RA exhibit distinct clinical courses and therapeutic responses, supporting precision‐guided treatment strategy development in RA. image

  • Open Access

    Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis–Associated Interstitial Lung Disease Risk

    by Kelsey Coziahr, Austin M. Wheeler, Brent A. Luedders, Michael Duryee, Halie Frideres, Katherine D. Wysham, Grant W. Cannon, Gary Kunkel, Dana P. Ascherman, Paul A. Monach, et al.

    Objective: The purpose was to evaluate a biomarker score consisting of MUC5B rs35705950 promoter variant, plasma matrix metalloproteinase‐7 (MMP‐7), and serum anti–malondialdehyde‐acetaldehyde (anti‐MAA) antibody for rheumatoid arthritis (RA)–associated interstitial lung disease (ILD) risk stratification. Methods: Using a multicenter cohort of US veterans with RA, we performed a cross‐sectional study of prevalent RA‐ILD and a cohort study of incident RA‐ILD. Medical records were used to confirm clinical ILD diagnoses by chest imaging or lung biopsy pathology reports. A combined three‐biomarker score (range 0–3) was calculated based on the presence of the MUC5B variant and elevations (upper 25% vs lower 75%) in MMP‐7 and anti‐MAA antibody concentrations. Multivariate logistic and Cox regression models were adjusted for clinical risk factors. Results: Among 2,043 participants with RA, prevalent ILD was identified in 88 (88.7% male; mean age 63.6 years). The odds of prevalent RA‐ILD were higher with increased biomarker score (adjusted odds ratio 12.21 [95% confidence interval (CI) 3.82–38.97] for score of 3 vs 0). A score ≥1 had 76.1% sensitivity but 48.6% specificity. Incident RA‐ILD developed in 148 participants, with those having a combined biomarker score of 3 having the highest risk (adjusted hazard ratio 4.36 [95% CI 1.55–12.27]). The area under the curve for prevalent RA‐ILD and Harrell's C for incident RA‐ILD were highest when clinical risk factors were combined with the biomarker score. Conclusion: This three‐analyte biomarker score was associated with both prevalent and incident RA‐ILD, improving risk stratification beyond clinical risk factors. Although this score is inadequate for clinical implementation, these findings demonstrate the potential for biomarker scores in RA‐ILD risk stratification.


  • Open Access

    Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis–Associated Interstitial Lung Disease

    by Cristina M. Padilla, Robert Lafyatis, Kevin F. Gibson, Christina Morse, Eleanor Valenzi, Xiaoping Chen, Xiaoyun Li, Yanwu Zhao, Yongseok Park, Dana Ascherman, et al.

    Objective: A leading cause of death among patients with scleroderma (SSc), interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool. We aimed to identify gene signatures that would predict progressive ILD. Methods: We compared previously identified serum biomarkers, bulk peripheral blood mononuclear cell (PBMC) RNA gene expression (39 patients with progressive SSc‐ILD and 43 patients with stable SSc‐ILD), and single‐cell RNA gene expression of PBMC (13 patients with progressive SSc‐ILD, 14 patients with stable SSc‐ILD, and 6 control participants). Results: In previous studies, male sex, Krebs von den Lungen 6 levels, and C‐reactive protein levels were predictors of progressive disease in patients. Monocyte expression of lipoxygenase homology domains 1 (LOXHD1) and Ras homolog gene family, member B (RHOB) strongly predicted progression, suggesting a key role in immune dysregulation. LOXHD1 and related genes were enriched in inflammatory gene networks, which may support monocyte‐associated inflammation in patients. RHOB was consistently up‐regulated in both CD14+ and CD16+ monocytes across single‐cell and bulk RNA data, underscoring robust association with progressive disease. In contrast, ataxin‐2‐like (ATXN2L) protein was down‐regulated in patients with progressive disease, suggesting dysregulation of cellular stress responses. Additionally, S100 calcium‐binding protein A12 (S100A12), chitinase‐3‐like protein 1 (CHI3L1), and matrix metalloproteinase‐9 (MMP9), previously linked to tissue remodeling, were again associated with progression in bulk RNA sequencing and previous microarray studies, reinforcing their role in fibrosis. Conclusion: With several potential biomarkers of progressive disease in patients, the next step includes validation in larger, multicenter cohorts for use in clinical decision‐making.


  • Open Access

    Revisiting the INSPIRE trial: antibody profiling reveals high prevalence of occult autoimmunity

    by Marilyn K. Glassberg, Cindy Burg, Simone Pereira-Simon, Benjamin Trzaskoma, Lisa Harlow, Stephanie Biedka, Sharon Elliot, Yingze Zhang, Hannah VanEvery, Noreen Fertig, et al.

    In the INSPIRE trial, patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) failed to demonstrate improved survival after treatment with IFN-gamma-1&

  • Open Access

    Performance of an Idiopathic Pulmonary Fibrosis–Derived Multibiomarker Panel for Rheumatoid Arthritis–Associated Interstitial Lung Disease

    by Brent A. Luedders, Daniel Kass, Joshua F. Baker, Michael J. Duryee, Yangyuna Yang, Punyasha Roul, Halie Frideres, Katherine D. Wysham, Paul A. Monach, Andreas Reimold, et al.

    Objective: To assess whether a panel of peripheral blood biomarkers associated with idiopathic pulmonary fibrosis (IPF) is also associated with interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) using three independent cohorts. Methods: We first assessed the association of a panel of IPF‐associated biomarkers with prevalent ILD among two separate RA cohorts (n = 93 and n = 71). Concentrations of eight IPF‐related biomarkers (eotaxin, Flt‐3L, interleukin‐8, macrophage‐derived chemokine, monocyte chemoattractant protein 1, and matrix metalloproteinase 2/7/9 [MMP‐2/7/9]) were measured, standardized, and summed to generate a multibiomarker score. We subsequently validated the association of this score (minus MMP‐2) with prevalent and incident ILD in an independent multicenter prospective cohort of US veterans with RA (n = 2,507). Multivariable regression models were adjusted for relevant covariates in the validation cohort. Results: In both development cohorts, participants with RA‐ILD had significantly higher IPF multibiomarker scores than those with RA alone. In the independent validation cohort, participants in the highest quartile of multibiomarker scores had a significantly higher likelihood of prevalent ILD (adjusted odds ratio 2.14 [95% confidence interval 1.18–3.87]) and incident ILD (adjusted hazard ratio 2.45 [95% confidence interval 1.55–3.88]) than those in the lowest quartile. The cumulative hazard of incident ILD approached 20% by 15 years for those in the highest quartile, compared to <10% for all other quartiles. Conclusion: A multibiomarker panel derived from IPF‐associated biomarkers was associated with RA‐ILD in separate development and validation cohorts. This overlap supports the concept of shared etiopathogenesis of IPF and RA‐ILD and illustrates the potential for peripheral blood biomarker panels to stratify ILD risk among patients with RA.


  • Open Access

    Refractory Anti‐HMGCR Necrotizing Myopathy With Progressive Hypercapnic Respiratory Failure Responsive to a JAK Inhibitor

    by N. Huang, T. B. George, L. Christopher-Stine, A. Nicolas, C. Oddis, D. P. Ascherman, V. M. Liarski

    Immune‐mediated necrotizing myopathy (IMNM) associated with 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) antibodies is a rare condition often associated with statin use. It typically presents with proximal weakness and markedly elevated creatine phosphokinase (CPK) levels and is often refractory, requiring long‐term immunotherapy. Respiratory involvement is uncommon but can be life‐threatening. Herein, we report the case of a 73‐year‐old woman with long‐standing anti‐HMGCR antibody–positive IMNM, refractory to glucocorticoids, methotrexate, azathioprine, intravenous immunoglobulin (IVIg), rituximab, and plasma exchange (PLEX), who presented with progressive hypercapnic respiratory failure. Despite ongoing treatment with IVIg, PLEX, and high‐dose glucocorticoids, the patient’s respiratory function worsened, and she required mechanical ventilation (MV). The addition of tofacitinib, a Janus kinase (JAK) inhibitor, coincided with marked clinical improvement, discontinuation of MV, and successful transition to room air. The patient continued to do well on this therapy, with improvement in muscle strength until outpatient discharge. The clinical benefit of JAK inhibition has been reported in dermatomyositis, overlap myositis, and anti–MDA5‐positive disease, particularly in refractory cases with pulmonary or systemic involvement—but has not been described in the setting of refractory IMNM. In our patient, who had exhausted multiple conventional therapies and PLEX, the rapid clinical improvement after JAK inhibition strongly suggests a therapeutic effect and highlights the need for future studies of JAK inhibitors in IMNM.


  • Quantifying Cutaneous Dermatomyositis: A Novel 3D Image–Based Approach

    by Nantakarn Pongtarakulpanit, Anuradha Bishnoi, Tanya Chandra, Sedin Dzanko, Eugenia Gkiaouraki, Shiri Keret, Raisa Lomanto Silva, Shreya Sriram, Didem Saygin, Vladimir M. Liarski, et al.

    Objective: Visual examination of skin lesions has considerable subjectivity and interrater variability. This study assessed the feasibility of a 3D image–based assessment of cutaneous disease activity in dermatomyositis (DM). Methods: Patients with DM were evaluated in a prospective study at 2 timepoints for skin rash assessment using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and 3D images. A 3D image disease activity score (3DAS) was calculated based on the percentage of the rashes relative to the total body surface area, multiplied by the degree of rash redness. The construct validity and responsiveness of 3DAS were evaluated using the Spearman correlation coefficient ( r ) against standard CDASI and patient-reported outcome measures (PROMs). A generalized linear regression model assessed the relationship between the 3D image–derived rash area and redness with the CDASI score. Results: Twenty-seven patients with DM (81.5% female, 96.3% White; median age 50.0 years) were enrolled. The median (IQR) CDASI score at baseline was 6.0 (IQR 0.0-17.0). For the construct validity, 3DAS correlated strongly with the CDASI ( r = 0.83; P < 0.001) and PROMs. The generalized linear regression analysis identified the rash area and redness from 3D images as significant predictors of the CDASI score. Regarding responsiveness, absolute changes from baseline in the 3DAS correlated strongly with the CDASI score ( r = 0.61; P = 0.004). Conclusion: Our results demonstrate favorable validity and responsiveness of the 3D images for evaluating rashes in patients with DM. The 3D image–derived rash area and redness are significant predictors of CDASI scores.

  • Open Access

    Editorial: New insights into the pathogenesis of idiopathic inflammatory myopathy

    by Dana P. Ascherman

    Over the last several years, application of these newer tools and technologies have begun coming to fruition. Advancements include the characterization of K 2p 2.1, a potassium channel that may regulate influx of inflammatory cells into diseased muscle tissue (1), and provocative studies demonstrating the ability of autoantibodies to penetrate cells and inhibit key cellular processes impacting transcriptional regulation and downstream signaling pathways (2). In this special section focusing on the pathogenesis of IIM, the brief compendium of manuscripts highlight additional avenues of discovery that have advanced our understanding of aberrant immune responses and metabolic profiles characterizing different disease subtypes. For example, Wang et. al. present data demonstrating the ability of various byproducts of glycerophospholipid metabolism and fatty acid oxidation to distinguish different antibody subgroups of dermatomyositis, high versus low disease activity, and the presence versus absence of interstitial lung disease. Demonstrating the complementary application of single cell RNA sequencing of peripheral blood mononuclear cells (PBMC), the analyses presented by Ding et. al. provide compelling insight to differences in immune landscape (cellular profile, cytokine signaling pathways) and metabolic derangements between patients with antisynthetase antibody-positive dermatomyositis and anti-MDA5 antibody-positive dermatomyositis. In a different approach, Bolko et. al. use single molecule array (SIMOA) and ELISA to characterize Type I interferon profiles in different autoantibody subsets of dermatomyositis-with results demonstrating subset-dependent correlations of IFNα and/or IFNβ with disease activity. Finally, Gao et. al. examine clinical, immunological, and demographic risk factors associated with risk of Pneumocystis jirovecii infection (documented by metagenomic sequencing) and poor outcome in MDA5 antibody-positive dermatomyositis. Collectively, these studies demonstrate the power of different omics approaches in elucidating pathogenically-relevant pathways in IIM and offer hope of defining newer, desperately needed therapeutic targets.